Please login to the form below

Not currently logged in

Novo's world-leading insulin plant to get even bigger

Danish firm invests €54m in Kalundborg expansion
Novo Nordisk Kalundborg

Novo Nordisk's product plant in Kalundborg, Denmark - already the largest insulin manufacturing site in the world - is set for further expansion.

The Danish diabetes specialist is investing DKK 400m (around €54m) to enlarge the site on the northwestern coast of Zealand by 500m2.

Michael Hallgren, senior vice president and head of production in Kalundborg, said: "The expansion of our production plant highlights our ambition to continue strengthening our presence in Kalundborg.

“The new facilities will give us greater flexibility and enable the installation of equipment that will enhance efficiency and increase the long-term production capacity of the plant.”

The site, which employs some 3,400 people, is a cornerstone of Novo's global production and produces 50% of the world's insulin as well as a range of biopharmaceutical products.

The investment in the plant comes just over a month after Novo won unanimous backing from FDA advisors for the approval of IDeglira, its once-daily, fixed-dose combination Tresiba (insulin degludec) and Victoza (liraglutide).

A groundbreaking for the Kalundborg plant's extension will take place today and work is expected to be completed by the end of 2018.

Article by
Dominic Tyer

4th July 2016

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...